|Adherence to protease inhibitor therapy and outcomes in patients with HIV infection|
DL Paterson, S Swindells, J Mohr, M Brester, EN Vergis, C Squier, ...
Annals of internal medicine 133 (1), 21-30, 2000
|Updated research nosology for HIV-associated neurocognitive disorders|
A Antinori, G Arendt, JT Becker, BJ Brew, DA Byrd, M Cherner, DB Clifford, ...
Neurology 69 (18), 1789-1799, 2007
|Combination antiretroviral therapy and the risk of myocardial infarction|
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
|Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study|
R Weber, CA Sabin, N Friis-Moller, P Reiss, WM El-Sadr, O Kirk, F Dabis, ...
Arch Intern Med 166 (15), 1632-41, 2006
|Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients|
AA Monforte, AC Lepri, G Rezza, P Pezzotti, A Antinori, AN Phillips, ...
Aids 14 (5), 499-507, 2000
|Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature.|
|Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.|
A Ammassari, R Murri, P Pezzotti, MP Trotta, L Ravasio, PL De, SC Lo, ...
Journal of acquired immune deficiency syndromes (1999) 28 (5), 445-449, 2001
|Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b …|
B Clotet, J Feinberg, J Van Lunzen, MA Khuong-Josses, A Antinori, ...
The Lancet 383 (9936), 2222-2231, 2014
|Late presentation of HIV infection: a consensus definition|
A Antinori, T Coenen, D Costagiola, N Dedes, M Ellefson, J Gatell, ...
HIV medicine 12 (1), 61-64, 2011
|Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …|
L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ...
The Lancet infectious diseases 11 (5), 363-371, 2011
|Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.|
F Starace, A Ammassari, MP Trotta, R Murri, PL De, C Izzo, A Scalzini, ...
Journal of acquired immune deficiency syndromes (1999) 31, S136-9, 2002
|Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons|
A Ammassari, A Antinori, MS Aloisi, MP Trotta, R Murri, L Bartoli, ...
Psychosomatics 45 (5), 394-402, 2004
|Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects|
A De Luca, R Bugarini, AC Lepri, M Puoti, E Girardi, A Antinori, A Poggio, ...
Archives of internal medicine 162 (18), 2125-2132, 2002
|Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors|
V Tozzi, P Balestra, R Bellagamba, A Corpolongo, MF Salvatori, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 45 (2), 174-182, 2007
|Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)|
A Cingolani, A Antinori, MG Rizzo, R Murri, A Ammassari, F Baldini, ...
Aids 16 (3), 369-379, 2002
|Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays …|
A Antinori, A Ammassari, A De Luca, A Cingolani, R Murri, G Scoppettuolo, ...
Neurology 48 (3), 687-694, 1997
|Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy|
A Antinori, A Cingolani, L Alba, A Ammassari, D Serraino, BC Ciancio, ...
Aids 15 (12), 1483-1491, 2001
|Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America|
Antiretroviral Therapy Cohort Collaboration
Clinical Infectious Diseases 41 (12), 1772-1782, 2005
|All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort …|
Collaboration of Observational HIV Epidemiological Research Europe (COHERE ...
International journal of epidemiology 41 (2), 433-445, 2011
|The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation …|
LM Larocca, D Capello, A Rinelli, S Nori, A Antinori, A Gloghini, ...
Blood 92 (3), 1011-1019, 1998